Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Exclusion Criteria

• •A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment or breast-feeding women
• •Concomitant use of strong inhibitors and inducers of CYP1A2, 2J2, 2C19, 2D6, and 3A4/5 within the timeline duration of five half-lives prior to starting study drug and throughout the trial
• •Concomitant use of sensitive substrates of CYP2C9, 2C19, and 3A4 within the timeline duration of five half-lives prior to starting study drug and throughout the trial
• •Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis
• •Has had an allogeneic tissue/solid organ transplant